Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63187-720

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63187-720). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in Duloxetine Delayed-Release capsules. The diagram shows the molecular structure including aromatic rings and the hydrochloride moiety.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Four treatment groups are compared: CYM 60 mg BID, CYM 60 mg QD, CYM 20 mg QD, and Placebo. The graph depicts how the percentage of patients improved decreases as the percent improvement in pain increases, with the placebo group consistently showing lower improvement compared to the CYM treatment groups.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: CYM 60mg BID, CYM 60mg QD, and Placebo. The graph shows trends of patient pain improvement percentages across different pain reduction thresholds.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved by percent improvement in pain from baseline (BOCF). Two data series are plotted: Placebo and CYM60/120 mg once daily. The y-axis represents the percentage of patients improved, ranging from 0 to 100%. The x-axis represents percent improvement in pain from baseline, marked in increments from 0 to 100%. The graph illustrates higher patient improvement percentages for CYM60/120 mg once daily compared to placebo across most improvement levels.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between two groups: placebo and CYM60 mg once daily. The x-axis shows percent improvement in pain from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Two lines represent the groups, with CYM60 showing consistently higher patient improvement percentages than placebo across the range.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for placebo and CYM60/120 mg once daily. The graph shows two lines representing patient improvement trends across increasing pain improvement thresholds.*

FDA Label Image

63187-720-60 (Duloxetine 07)

DULOXETINE DELAYED-RELEASE 20 mg capsules label, displaying the generic name duloxetine hydrochloride. The label states the product contains 60 delayed-release capsules, each with 22.4 mg of duloxetine hydrochloride equivalent to 20 mg duloxetine. It includes storage instructions (store at 25°C) and manufacturer information: Proficient Rx LP, Thousand Oaks, CA. The lot number, expiration date, and National Drug Code (NDC 63187-720-60) are shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.